LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug CombinationsGlobeNewsWire • 04/12/22
Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology's Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with ImmunotherapyGlobeNewsWire • 03/22/22
LIXTE Biotechnology Holdings, Inc. to Present at MedInvest Pharmaceutical and Biotechnology Investor ConferenceGlobeNewsWire • 03/16/22
Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100GlobeNewsWire • 01/12/22
Lixte Biotechnology's LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) TumorsGlobeNewsWire • 01/05/22
LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE'S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORSGlobeNewsWire • 11/22/21
Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer TreatmentGlobeNewsWire • 10/13/21
Lixte Biotechnology's LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine AddictionGlobeNewsWire • 08/17/21
Lixte Biotechnology Shares Are Trading Higher On Encouraging Preclinical LB-100 Data In Lung CancerBenzinga • 08/03/21
LIXTE BIOTECHNOLOGY'S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDYGlobeNewsWire • 08/03/21
LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISMGlobeNewsWire • 07/22/21
Lixte Biotechnology Comments on Outside Research Citing LB-100's PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast CancerGlobeNewsWire • 07/13/21
Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on July 14, 2021GlobeNewsWire • 07/07/21
Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung CancerGlobeNewsWire • 06/02/21
LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORSGlobeNewsWire • 05/12/21
Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference on May 20GlobeNewsWire • 05/04/21
Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of DirectorsGlobeNewsWire • 04/13/21
Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital ConferenceGlobeNewsWire • 03/03/21
WestPark Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)Business Wire • 03/02/21
